Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419375 | 0.79 | APLNR (0.45) | CA1CA2HTR2AAPLNR | |
| SCHEMBL1855842 | 0.77 | HTR2A (0.50) | MEN1KMT2ACA1CA2HTR2A | |
| SCHEMBL1921828 | 0.76 | TACR1 (0.49) | MEN1KMT2AHDAC8 | |
| SCHEMBL27312581 | 0.76 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL25474343 | 0.75 | APLNR (0.59) | MEN1KMT2APTPN7DUSP3HTR2A | |
| SCHEMBL25470888 | 0.75 | KDM4E (0.43) | MEN1KMT2APTPN7DUSP3CA1 | |
| SCHEMBL1599514 | 0.75 | TACR1 (0.54) | HTR2A | |
| SCHEMBL1436108 | 0.72 | PTPN1 (0.54) | MEN1KMT2A | |
| SCHEMBL4575343 | 0.72 | MEN1 (0.58) | MEN1KMT2APTPN7DUSP3 | |
| SCHEMBL27312595 | 0.72 | APLNR (0.68) | MEN1KMT2APTPN7DUSP3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1017387-A4 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030216377-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| CN-1114403-C | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-07-16 | — | — | CN | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030087894-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| US-20020128257-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| CN-1273529-A | Vitronection receptor antagonist | SMITHKLINE BEECHAM CORP (US) | 2000-11-15 | — | — | CN | disclosed |
| EP-1017387-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| CN-1238689-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999015170-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | MEN1 372/4885KMT2A 4439/4885PTPN7 1927/4885 |
| US-20030087894-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | MEN1 372/4885KMT2A 4439/4885PTPN7 1927/4885 |
| US-20020128257-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | MEN1 372/4885KMT2A 4439/4885PTPN7 1927/4885 |
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | MEN1 1246/4885KMT2A 4278/4885PTPN7 3376/4885 |
| US-20030216377-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | MEN1 372/4885KMT2A 4439/4885PTPN7 1927/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | MEN1 372/4885KMT2A 4439/4885PTPN7 1927/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | MEN1 1246/4885KMT2A 4278/4885PTPN7 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.